Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Does lipitor's use influence blood pressure medication type?
Drugpatentwatch skyrizi biologic patent analysis?
Pramlintide acetate price?
Quartette side effects?
Mebendazole ingredients?

Praluent 75 mg/ml?

See the DrugPatentWatch profile for Praluent

Praluent (Evolocumab) – 75 mg / mL injectable solution

Praluent is a monoclonal antibody that targets PCSK9 to lower LDL‑cholesterol. The commercial formulation sold by Amgen (and a few other manufacturers in some regions) is a 75 mg per 1 mL solution for subcutaneous injection.

1. Typical dosing regimen (US/Europe)

Indication Recommended dose Frequency Total weekly dose
Primary hypercholesterolemia (incl. familial) 140 mg (1.9 mL) Every 2 weeks 140 mg
Statin‑intolerant patients 140 mg (1.9 mL) Every 2 weeks 140 mg
Post‑MI / PAD / CAD patients 420 mg (5.6 mL) Every 4 weeks 420 mg

Note: Some patients may start at 140 mg every 2 weeks and switch to 420 mg every 4 weeks after a few months, depending on LDL‑C response.

2. How to administer

  1. Reconstitution – The vial already contains 75 mg / mL. No extra dilution is required.
  2. Injection volume – 1.9 mL (140 mg) or 5.6 mL (420 mg) per dose.
  3. Site – Subcutaneously in the abdomen, thigh, or upper arm (avoid the same spot each time).
  4. Needle – 0.5 – 1 cm needle (0.5–1 mm gauge).
  5. Technique – Pinch the skin, insert the needle at a 45° angle, and inject slowly.

3. What to look for

Issue What to watch Action
Injection site reactions (pain, redness, swelling) Mild, transient Use a different site; apply cold pack after injection.
Flu‑like symptoms Fever, chills, myalgia NSAIDs, rest; usually resolve in 24–48 h.
Hypersensitivity Rash, itching, anaphylaxis Stop injection, treat per protocol, notify prescriber.
Rare: Elevated transaminases Liver enzyme elevations Monitor LFTs; adjust dose if needed.

4. Key drug facts

  • Mechanism – Binds PCSK9, preventing its interaction with LDL‑R, increasing LDL‑R recycling.
  • Half‑life – ~11–14 days; allows bi‑weekly dosing.
  • Interactions – Minimal drug‑drug interactions; mainly antibody‑based, so no CYP metabolism.
  • Contraindications – Active infection, uncontrolled hypertension, known hypersensitivity to evolocumab or excipients.
  • Pregnancy / Lactation – Category B (limited data); use only if clearly needed.
  • Storage – Keep refrigerated (2–8 °C) before first use; can be stored at 20–25 °C for up to 30 days after the first dose (depending on the manufacturer’s labeling).

5. Common questions

Question Short answer
Can I self‑inject? Yes – most patients are trained to self‑inject.
What if I miss a dose? Inject as soon as remembered; if >1 week, follow your prescriber’s guidance.
What are the side‑effect odds? Injection‑site reactions ~10–20 %; flu‑like symptoms ~2–5 %.
Is it expensive? Yes – it’s a biologic, often cost‑effective when LDL‑C targets cannot be met by statins alone.

Bottom line

Praluent’s 75 mg/mL concentration is the standard injectable form used for treating high‑risk cardiovascular patients and those intolerant to statins. Follow the dosing schedule, administer subcutaneously, and monitor for common reactions. Always keep a close line of communication with your healthcare provider, especially when switching doses or reporting side‑effects.

If you need more individualized guidance or have specific concerns (e.g., pregnancy, comorbidities), let me know!



Other Questions About Praluent :

Does praluent cause muscle pain? Cost of praluent? When does the patent on praluent expire? How much does praluent cost without insurance? Praluent cost? Praluent patent expiration usa? Praluent us targetted population?

AI-Drug Label Prescribing Information Alignment Report

45
45%
Grade D

Poor

Not Aligned

Patient Risk: High

Summary

Multiple claims are not supported by the provided FDA label content, including a potentially dangerous dosing regimen (weekly 75 mg) and several adverse reaction and comparative/class statements that are not label-backed. Non-label patent/biosimilar statements were also included.

Category Scores

Indication
70
Partial
Dosage
30
Poor
Warnings
40
Poor
AdverseReactions
25
Poor
Administration
85
Good

Accurate Statements

Praluent 75 mg/mL is a formulation of alirocumab.
Supported by 11 DESCRIPTION (75 mg/mL contains 75 mg alirocumab).
Alirocumab is a PCSK9 inhibitor used to lower low-density lipoprotein (LDL) cholesterol levels.
Supported by 1 INDICATIONS AND USAGE (reduce LDL-C) and 12 CLINICAL PHARMACOLOGY (12.1).
Praluent is administered via subcutaneous injection.
Supported by 2.4 Important Administration Instructions and 11 DESCRIPTION.
In some cases, doses can be increased to 150 mg every two weeks.
Supported by 2.1 Recommended Dosage in Adults (adjust to 150 mg every 2 weeks if LDL-C response inadequate).
Alirocumab targets and inhibits the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action.
PCSK9 normally degrades LDL receptors on the surface of liver cells.
Supported by 12.1 Mechanism of Action.
By inhibiting PCSK9, alirocumab increases the number of LDL receptors available to clear LDL cholesterol from the bloodstream.
Supported by 12.1 Mechanism of Action.
Alirocumab reduces LDL-C levels.
Supported by 12.1 and 1 INDICATIONS AND USAGE (reduce LDL-C).

Unsupported Statements

In some cases, doses can be increased to 75 mg weekly if LDL cholesterol goals are not met.
Not supported by the provided label sections; 2.1 lists adjustments to 150 mg every 2 weeks (and adult 300 mg every 4 weeks option), not a weekly 75 mg regimen.
Praluent is prescribed to adults with very high LDL cholesterol due to heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH).
Partially supported at most; label indicates adjunct to reduce LDL-C in adults with HeFH/HoFH, but the claim wording 'very high LDL cholesterol' is not explicitly supported by the provided label text.
Praluent is prescribed to adults with established cardiovascular disease who need additional LDL-C lowering.
Partially supported; label includes reducing risk of major adverse CV events in adults at increased risk, and LDL-C reduction as adjunct therapy, but the specific phrasing 'established cardiovascular disease who need additional LDL-C lowering' is not directly supported by the provided label text.
Praluent is used in conjunction with diet and maximally tolerated statin therapy.
The label excerpt supports 'adjunct to diet and exercise' and describes background lipid-modifying therapy in clinical trial context, but 'maximally tolerated statin therapy' as a general labeled requirement is not explicitly supported by the provided label text for dosing/indication.
Common side effects reported with Praluent include nasopharyngitis.
Not supported by the provided label excerpt for adverse reactions; the provided 6.2 postmarketing list includes 'Influenza-like illness' and 'Angioedema' only.
Common side effects reported with Praluent include injection site reactions such as redness, bruising, or pain.
Not supported by the provided label excerpt; injection-site reaction details (redness/bruising/pain) are not present in the supplied adverse reaction text.
Serious allergic reactions are rare but possible with Praluent.
Not supported as stated ('rare'); label provided describes hypersensitivity reactions and contraindications but does not state rarity.
Praluent (alirocumab) and Repatha (evolocumab) are both PCSK9 inhibitors.
Not supported by the provided Praluent labeling text; no evolocumab/Repatha content is included in the supplied label sections.
Praluent and Repatha have similar mechanisms of action and indications for lowering LDL cholesterol.
Not supported by the provided label text; no Repatha comparative/mechanism/indication content is included.
Clinical studies have shown both Praluent and Repatha to be effective in reducing LDL cholesterol.
Not supported by the provided label text; the supplied label excerpt does not include any Repatha study claims.
The earliest expected patent expiration for alirocumab is in 2027.
Not label content; no patent timing information is present in the provided label sections.
Subsequent patents may extend patent protection for alirocumab beyond the earliest expected expiration.
Not label content; patent timing/extension statements are absent from provided label sections.
Patent expiry dates can be subject to legal challenges and variations in different regions.
Not label content; absent from provided label sections.
Biosimilars for Praluent can be developed once key patents expire.
Not label content; absent from provided label sections.
Biosimilar development and approval require demonstrating high similarity to the reference product in terms of quality, safety, and efficacy.
Not label content; absent from provided label sections.

Contradictions

High

AI Statement
In some cases, doses can be increased to 75 mg weekly if LDL cholesterol goals are not met.

Label Reference
2.1 Recommended Dosage in Adults

Important Omissions

Recommended adult starting dose is presented in the label as either 75 mg once every 2 weeks OR 300 mg once every 4 weeks (not just 75 mg/2 weeks).
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
The inclusion of an unsupported weekly 75 mg regimen could mislead dosing. Additional unsupported adverse reaction frequency/specificity claims could distort risk communication.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Unsupported dosing regimen (75 mg weekly) and multiple adverse reaction/comparator/patent statements not present in the provided FDA label excerpts.

Suggested Improvement
Limit claims to the supplied label sections: use the label-supported adult dosing options (75 mg q2 weeks or 300 mg q4 weeks; adjust to 150 mg q2 weeks when indicated), avoid unsupported 'common' adverse reaction claims, and remove non-label patent/biosimilar statements and Repatha comparative assertions.

Drug Brand Mention Assessment

Branding Score
74
Visibility
82
Mentioned
Ranking
#1
Sentiment
72
Recommendation Status
mentioned only
Brand Perception
Best Known For

a PCSK9 inhibitor used to lower low-density lipoprotein (LDL) cholesterol levels

Core Claims
  • Praluent 75 mg/mL is a formulation of alirocumab
  • It is administered via subcutaneous injection
  • It lowers LDL cholesterol levels
  • It targets and inhibits PCSK9
  • It is prescribed for adults with very high LDL cholesterol or established cardiovascular disease needing additional LDL-C lowering
Differentiators
  • Alirocumab is a PCSK9 inhibitor
  • Increases LDL receptors by inhibiting PCSK9
  • Dosing can be increased to 150 mg every two weeks or 75 mg weekly if goals are not met
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Repatha 23%
55 #2 No